11 research outputs found
The role of IAEA in preparation of recommendations for the use of PET/CT in radiotherapy planning
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints
Recist criteria for radiological avaluation of response in treatment in solid tumors
Specific anticancer therapy is very complicated, expensive and toxic treatment. Terms as complete response, partial response, stable disease etc. are usually necessary in clinical trials for evaluation of treatment outcome, enabling the therapist to apply the most effective treatment
Concomitant 3D-radiotherapy (3D-RT) with cisplatin (P) for advanced paranasal sinus carcinoma
Experience of Muslims in Eastern Europe
The chapter addresses the evolution of Islamic presence and Muslim experiences in two dozen post-socialist countries collectively comprising the region of Eastern Europe. In the first part, it traces the arrival of Islam and settlement of Muslims in this part of Europe through intermittent waves of migration, conversion, and conquest, their historical status, and governance of Islam in such empires as the Russian and Ottoman and later the communist-ruled USSR, SFRY, and other states. It then proceeds to the analysis of the contemporary situation of Muslims in the region through the prism of common phenomena, like forms and levels of religiosity among region’s Muslims, (re)institutionalization of Islam in post-socialist Eastern European states, depopulation of the Muslim segment through emigration, assimilation and other natural causes, radicalization of certain segments of national Muslim populations, (re)emergence of Islamophobia on the part of non-Muslim populations, and securitization of Islam by national governments and other actorsRegionistikos katedraVytauto Didžiojo universiteta
Access to innovative medicines for metastatic melanoma worldwide:Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found